Pre-Operative Endocrine Therapy Shows Promise For Breast Cancer
[09/05/2001; Doctor's Guide]
Ongoing clinical trials show survival in breast cancer patients
is equal between preoperative as with postoperative adjuvant
Preoperative (neoadjuvant) medical therapy has emerged over the
past decade as a new approach for early breast cancer, points
out Dr Ian Smith, Professor of Cancer Medicine, and colleagues
at the Breast Unit, Royal Marsden Hospital, London England.
"Results show it has high activity, but survival is no better
than with conventional adjuvant treatment," he and colleagues
add in a detailed review of the state of neoadjuvant therapy.
"The need for mastectomy is reduced but not abolished; in some
studies this effect is associated with a small increase in risk
of local recurrence, but without any detriment to survival."
The aim is to define short-term surrogate markers predictive of
long-term outcome. "Such markers may be biological rather than
clinical, since the latter may prove too insensitive," Dr Smith
points out. "If such markers can be established, then treatment
can be individualised for each patient, with potential survival
|Remember we are NOT Doctors and have NO medical training.|
This site is like an Encyclopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.